bioRxivPharmacology & Toxicology
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.
J. Tobacyk, B. J. Parks, P. Salazar, L. Coward, M. D. Berquist, G. S. Gorman, L. K. Brents
Abstract
Buprenorphine (BUP) is the preferred treatment for opioid use disorder during pregnancy but can cause neonatal opioid withdrawal syndrome (NOWS). Norbuprenorphine (NorBUP), an active metabolite of BUP, is implicated in BUP-associated NOWS. We hypothesized that BUP, a low-efficacy agonist of mu opioid receptors, will not antagonize NorBUP, a high-efficacy agonist of mu opioid receptors, in producing NOWS. To test this hypothesis, we treated pregnant Long-Evans rats with BUP (0, 0.01, 0.1 or 1 mg/kg/day) {+/-} NorBUP (1 mg/kg/day) from gestation day 9 until pup delivery, and tested pups for opioid dependence using our established NOWS model. We used LC-MS-MS to quantify brain concentrations of BUP, NorBUP, and their glucuronide conjugates. BUP had little effect on NorBUP-induced NOWS, with the exception of 1 mg/kg/day BUP significantly increasing NorBUP-induced NOWS by 58% in females. BUP and NorBUP brain concentrations predicted NOWS in multiple linear regression models. Interestingly, NorBUP contributed more to NOWS in females ({beta}NorBUP = 51.34, p = 0.0001) than in males ({beta}NorBUP = 19.21, P = 0.093), while BUP was similar for females ({beta}BUP = 10.62, P = 0.0017) and males ({beta}BUP = 11.38, P = 0.009). We are the first to report that NorBUP induces NOWS in the presence of BUP and that there is sexual divergence in the contribution of NorBUP to BUP-associated NOWS. These findings suggest that females are more susceptible to NorBUP-induced NOWS, and that treatment strategies that reduce prenatal NorBUP exposure may be more effective for females than males. O_LIBuprenorphine does not antagonize fetal norbuprenorphine dependence. C_LIO_LIIn females, buprenorphine and norbuprenorphine have an additive effect. C_LIO_LINorbuprenorphine contributes to NOWS in females more than in males. C_LIO_LIThe glucuronide of norbuprenorphine accumulates in fetal brain. C_LIO_LIThe glucuronide of buprenorphine does not accumulate in fetal brain. C_LI
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
V. Janganati, P. Salazar, … L. K. Brents·bioRxiv·Dec 12, 2022
- Acute buprenorphine exposure depresses neonatal respiratory chemoreflexes in the presence or absence of naloxone
Michael L. Frazure, Khushi Praveen, … Ralph Frank Fregosi·bioRxiv·May 17, 2026
- Pharmacological prevention of neonatal opioid withdrawal in a pregnant guinea pig model.
A. Safa, A. R. Lau, … J. Oberdick·bioRxiv·Jul 25, 2020
- Buprenorphine exposure alters the development and migration of interneurons in the cortex
Vanesa Nieto‐Estévez, Jennifer J. Donegan, … Jenny Hsieh·Frontiers in Molecular NeurosciencePeer-reviewed·May 4, 2022
- Perinatal Oxycodone Exposure Causes Long Term Sex-Dependent Changes in Sensory and Reward Processing in Adult Mice
Elena Minakova, Marwa O. Mikati, … Ream Al‐Hasani·bioRxiv·Feb 15, 2022
- Sex differences in behavioral and brainstem transcriptomic neuroadaptations following neonatal opioid exposure in outbred mice
Kristyn N. Borrelli, Emily J. Yao, … Camron D. Bryant·eNeuroPeer-reviewed·Sep 1, 2021